Welcome to our dedicated page for Envveno Med SEC filings (Ticker: NVNBW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NVNBW SEC filings page on Stock Titan aggregates regulatory documents connected to ENVVENO MEDICAL CP WT 26 and its underlying issuer, enVVeno Medical Corporation. These filings, drawn from the SEC’s EDGAR system, include Forms 8-K, Definitive Proxy Statements on Schedule 14A, and references to shelf registration statements and prospectus supplements. Together, they provide a detailed record of how the company reports material events, stockholder actions, capital raising arrangements, and regulatory developments.
Form 8-K filings from 2025 illustrate several important themes. One 8-K dated October 10, 2025 discloses a Nasdaq notice that the company’s common stock no longer met the minimum $1.00 bid price requirement for continued listing on the Nasdaq Capital Market, and explains the 180-day compliance period, possible additional 180-day extension, and the potential role of a reverse stock split in curing the deficiency. Later 8-K filings dated December 12, 2025 report the results of the 2025 Annual Meeting of Stockholders, including director elections, an advisory vote on executive compensation, ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, the rejection of the 2025 Equity Incentive Plan, and stockholder authorization for the Board of Directors to implement a reverse stock split within a specified ratio range.
Another 8-K dated October 30, 2025 describes an At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., under which the company may sell shares of its common stock from time to time as at-the-market equity offerings pursuant to an effective Form S-3 registration statement and a filed prospectus supplement. This filing also lists related exhibits, including the agreement itself and a legal opinion on the validity of the shares. An 8-K dated November 20, 2025 details an amendment to the company’s Amended and Restated Bylaws, revising the quorum requirement for stockholder meetings to a specified percentage of voting power, subject to applicable law and charter provisions.
Regulatory and product matters appear in an 8-K dated November 13, 2025, which reports that the company issued a press release about an unfavorable FDA appeal decision on its Premarket Approval application for VenoValve®, described as a surgical replacement venous valve for treating severe deep chronic venous insufficiency. The company notes that the press release is furnished as an exhibit, and the related Definitive Proxy Statement discusses a broader appeal process and its implications for both VenoValve and enVVe, a next generation transcatheter replacement venous valve.
On this NVNBW filings page, Stock Titan presents these documents with AI-powered summaries that help explain the significance of each filing. Investors can quickly see how stockholder votes affected equity incentive plans and reverse stock split authority, how the company structures at-the-market equity offerings, and how listing compliance issues and FDA-related outcomes are disclosed. The page also surfaces information relevant to monitoring governance practices, auditor relationships, bylaw changes, and other material events reported by enVVeno Medical Corporation in connection with the security associated with NVNBW.
enVVeno Medical Corporation reported that its Board of Directors approved an amendment to the company’s Amended and Restated Bylaws. The change updates the quorum requirement for stockholder meetings.
Under the revised Section 1.5, a stockholder meeting will have a quorum when holders present in person or by proxy represent thirty-three and one-third percent of the voting power of the outstanding shares entitled to vote, unless a higher threshold is required by law, the certificate of incorporation, or the bylaws. The amendment became effective immediately upon Board approval on November 17, 2025.
enVVeno Medical Corporation (NVNO) disclosed that investor Thomas A. Satterfield, Jr. has filed a Schedule 13G reporting beneficial ownership of 1,822,500 shares of common stock, representing 9.0% of the outstanding shares, based on 20,216,176 shares outstanding as of October 28, 2025. Satterfield has sole voting and dispositive power over 165,000 shares and shared voting and dispositive power over 1,657,500 shares.
The filing explains that 400,000 shares are held through Tomsat Investment & Trading Co., Inc., wholly owned by Satterfield, and 1,250,000 shares are held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity in which he owns a 50% interest and serves as Chief Investment Manager. He certifies that the securities were not acquired for the purpose of changing or influencing control of enVVeno, indicating a passive investment stance.
Nantahala Capital Management, Wilmot B. Harkey, and Daniel Mack filed Amendment No. 2 to Schedule 13G for enVVeno Medical (NVNO). They report beneficial ownership of 688,940 shares of common stock, representing 3.46% of the class, as of September 30, 2025.
The reporting persons have shared voting and shared dispositive power over these shares, with no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.
enVVeno Medical (NVNO) reported that it received an unfavorable appeal decision from the U.S. Food & Drug Administration regarding its Premarket Approval (PMA) application for VenoValve, a surgical replacement venous valve intended to treat severe deep chronic venous insufficiency. The company disclosed this update under Regulation FD.
The announcement was furnished via an accompanying press release included as Exhibit 99.1. The filing reiterates standard forward‑looking statement cautions.
enVVeno Medical Corporation established an at-the-market equity program, allowing it to sell up to $50,000,000 of common stock from time to time through Ladenburg Thalmann as sales agent. The agent will receive a fixed 3% commission on gross proceeds from each sale. Sales may be made as “at-the-market” offerings under Rule 415, including ordinary brokers’ transactions on the NASDAQ Capital Market at market prices or as otherwise agreed. The company is not obligated to sell shares and may suspend or terminate the program.
The shares are covered by enVVeno’s effective Form S-3 (File No. 333-273546) declared effective on August 23, 2023, and a Prospectus Supplement filed on October 30, 2025. An opinion of counsel regarding the legality of the shares and the ATM Agreement were filed as exhibits.
enVVeno Medical Corporation is launching an at-the-market offering of up to $50,000,000 of common stock through Ladenburg Thalmann as sales agent under a Rule 424(b)(5) prospectus supplement. Sales may be made from time to time in transactions deemed “at the market,” and Ladenburg will earn a 3% commission on gross proceeds.
The stock trades on Nasdaq as NVNO; the last reported sale price was $0.7188 per share on October 29, 2025. “The Offering” section illustrates that at this price, selling 69,560,378 shares would raise $50,000,000, with actual share issuance varying by sale prices. Shares outstanding were 20,216,176 as of October 29, 2025.
Net proceeds are intended primarily to fund development of VenoValve and enVVe, and for general corporate purposes, including working capital and potential complementary acquisitions. The company also disclosed a Nasdaq minimum bid price deficiency notice dated October 7, 2025, with an initial compliance period through April 6, 2026.
enVVeno Medical (NVNO) filed its 2025 proxy for a virtual annual meeting on December 11, 2025 at 9:00 AM PST via www.virtualshareholdermeeting.com/NVNO2025. Stockholders of record at the close of business on October 17, 2025 may vote; there were 20,216,176 shares outstanding on the record date.
Stockholders will vote on four items: elect two Class II directors (Matthew M. Jenusaitis and Robert A. Berman) to terms ending in 2028; approve, on a non-binding advisory basis, executive compensation; ratify CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2025; and approve the 2025 Equity Incentive Plan. The Board unanimously recommends voting “FOR” all proposals.
The materials note an ongoing FDA supervisory appeal regarding the not‑approvable decision for the VenoValve in the U.S. The appeal request was filed on September 18, 2025, an in‑person FDA meeting was held, and the Company is on track to hear from the FDA about this stage of the appeal process by the end of 2025. The outcome may also inform enVVe, the next‑generation transcatheter valve.
enVVeno Medical (NVNO) filed its Q3 2025 10‑Q, reporting a net loss of $4.5 million as operating expenses declined. Research and development was $2.6 million and selling, general and administrative was $2.3 million for the quarter, reflecting lower legal costs and a partial recovery of previously reserved clinical prepayments.
Cash and investments totaled $31.0 million with working capital of $29.1 million as of September 30, 2025, and management believes resources are sufficient for at least one year. Shares outstanding were 20,216,176 as of October 28, 2025.
Regulatory updates: the FDA issued a not‑approvable letter for the VenoValve PMA on August 19, 2025; the company filed a supervisory appeal and met with FDA leadership in October, with a decision expected by year‑end 2025. Nasdaq notified the company on October 7, 2025 of non‑compliance with the $1.00 minimum bid price; NVNO has until April 6, 2026 to regain compliance.
enVVeno Medical Corporation reported that it received a notice from Nasdaq on October 7, 2025 stating that the company no longer meets the Nasdaq Capital Market’s minimum bid price requirement because its common stock closed below $1.00 per share for 30 consecutive business days. The notice does not immediately affect the stock’s Nasdaq listing.
The company has 180 calendar days, until April 6, 2026, to regain compliance by having its closing bid price at or above $1.00 per share for at least 10 consecutive trading days, a period Nasdaq may extend beyond 10 days at its discretion. If it still does not comply by that date, enVVeno may qualify for an additional 180-day period if it meets other Nasdaq initial listing standards and notifies Nasdaq of its plan to cure the deficiency, potentially including a reverse stock split. If Nasdaq ultimately determines compliance cannot be regained, the company’s stock could be delisted, although enVVeno would have the right to appeal.
Francis Duhay, a director of enVVeno Medical Corp, reported the sale of 4,900 shares of the issuer's common stock on 09/15/2025 under a Rule 10b5-1 trading plan adopted in June 2025. The transactions executed during the day at prices ranging from $0.8205 to $0.84, with a reported weighted-average price of $0.83.
After the reported sale, the reporting person beneficially owned 97,444 shares as of the transaction date. The Form 4 was signed on 09/17/2025 and includes an undertaking to provide full trade details on request to regulators or security holders.